Bruceantin

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameBruceantin
Drug Alias NameNSC-165563
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMyc proto-oncogene protein inhibitorsApoptosis inducers
TargetsMyc proto-oncogene protein
Therapy Area/IndicationsBreast NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsBreast NeoplasmsMelanoma

Other Information

ATC CodeN/A
Related LinksKEGG